Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 15/20 | 0.57 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.53 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176615 | 0.94 | ESR1 (0.67) | ESR1ESR2AKR1C3AKR1C1KDM2B | |
| SCHEMBL25734241 | 0.88 | HDAC1 (0.51) | ESR1ESR2AKR1C3AKR1C1KDM2B | |
| SCHEMBL25734238 | 0.82 | ESR2 (0.67) | ESR1ESR2AKR1C3AKR1C1KDM2B | |
| SCHEMBL3280649 | 0.82 | AKR1C3 (0.76) | ESR2AKR1C3AKR1C1 | |
| SCHEMBL3181883 | 0.80 | ESR2 (0.88) | ESR1ESR2AKR1C3KDM2BHRH3 | |
| SCHEMBL1413449 | 0.80 | ALDH1A1 (0.58) | AKR1C3ALDH1A1MYC | |
| SCHEMBL3184605 | 0.79 | ESR1 (0.62) | ESR1ESR2AKR1C3KDM2BALDH1A1 | |
| SCHEMBL3282591 | 0.79 | AKR1C3 (0.53) | AKR1C3AKR1C1 | |
| SCHEMBL3284957 | 0.79 | AKR1C3 (0.73) | ESR2AKR1C3AKR1C1 | |
| SCHEMBL4012085 | 0.79 | AKR1C3 (0.73) | AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | ESR1 2488/4885ESR2 823/4885AKR1C3 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.